The ADK Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of human HAP1 cells with targeted disruption of the ADK gene, providing a loss-of-function model for studying adenosine kinase activity. As a polyclonal knockout, the population retains genetic heterogeneity at the target locus, mimicking natural variation and reducing clone-specific artifacts. This heterogeneous pool is ideal for unbiased functional genomics and pathway screening.
HAP1 is a near-haploid human adherent cell line derived from KBM-7 chronic myeloid leukemia cells. Its haploid genome, except for a disomic fragment of chromosome 8, enables recessive genetic analysis by ensuring that single-gene knockout leads to complete loss-of-function phenotypes. The cell line??s adherent nature and ease of transfection facilitate diverse experimental workflows, while its close-to-haploid state simplifies interpretation of knockout phenotypes by eliminating heterozygous confounding effects.
Adenosine kinase catalyzes the phosphorylation of adenosine to AMP, acting as a pivotal regulator of adenosine concentration and purine nucleotide synthesis. ADK functions upstream of adenosine receptors (ADORA1, ADORA2A, ADORA2B, ADORA3) and is modulated by substrates (adenosine, ATP) and inflammatory signals such as TNF-??. ADK interacts with adenosine transporters like ENT1 (SLC29A1) and competes with ADA for substrate; thus, knockout profoundly shifts the balance toward adenosine accumulation. This excess adenosine signals through the four receptor subtypes, each coupling to distinct G protein pathways to regulate cAMP, PKA, and AMPK cascades, thereby influencing the methionine cycle and nucleotide salvage.
In the haploid HAP1 background, ADK knockout unambiguously dissects adenosine-driven signaling networks, relevant to adenosine kinase deficiency, hypermethioninemia, epilepsy, and liver disease. Elevated adenosine is associated with severe hepatic and neurological phenotypes, and this model facilitates exploration of ADK as a therapeutic target in these conditions and in modulating inflammatory responses. Additionally, the leukemia origin permits investigation of adenosine metabolism in cancer cell proliferation, immunosuppression, and metabolic reprogramming.
Applications include Western blotting for ADK protein, RT-qPCR for mRNA, and HPLC-based adenosine quantification. Functional assays such as cAMP measurement, metabolic flux analysis, Seahorse metabolic profiling, and cell viability screens enable detailed interrogation of adenosine receptor signaling and AMPK engagement. The knockout cells can be utilized in high-throughput screens to identify small-molecule modulators of adenosine signaling or metabolic vulnerabilities. For additional information, please contact Ascent Research.
